Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - eno od teh inaktivirano bolezni modrikastega jezika virus sevov:inaktivirano bolezni modrikastega jezika virus, serotip 1, sev btv-1/alg2006/01 e1inactivated bolezni modrikastega jezika virus, serotip 8, sev btv-8/bel2006/02inactivated bolezni modrikastega jezika virus, serotip 4, sev spa-1/2004 - immunologicals, immunologicals za bovidae, inaktivirano virusna cepiva, bolezen modrikastega jezika virus, ovce - sheep; cattle - aktivno imunizacijo ovc od 6 tednov starosti za preprečevanje viraemia zaradi bolezni modrikastega jezika virus, serotypes 1 in 8, in za zmanjšanje viraemia zaradi bolezni modrikastega jezika virus, serotip 4 in aktivno imunizacijo goveda (od 12. tedna starosti za preprečevanje viraemia zaradi bolezni modrikastega jezika virus, serotypes 1 in 8.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glaxosmithkline consumer healthcare (uk) trading limited - terbinafin - gel - terbinafin 10 mg / 1 g - terbinafin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glaxosmithkline consumer healthcare (uk) trading limited - terbinafin - gel - terbinafin 10 mg / 1 g - terbinafin

Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; hidradenitis suppurativa; arthritis - imunosupresivi - revmatoidni arthritisimraldi v kombinaciji z metotreksatom, je indicirano za:zdravljenje zmerno do hudo aktivnega revmatoidnega artritisa pri odraslih bolnikih, kadar je odziv na bolezni-spreminjanje anti-revmatičnih drog, vključno z metotreksatom je nezadostna. zdravljenje hude, aktivne in postopno revmatoidni artritis pri odraslih, ki še niso bila obdelana z metotreksatom. imraldi lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno. adalimumab je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisimraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab ni raziskano pri bolnikih, starih manj kot 2 leti. enthesitis-related arthritisimraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asimraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatični arthritisimraldi je primerna za zdravljenje aktivnega in postopno psoriatičnega artritisa pri odraslih, ko je odgovor na prejšnje bolezni spreminjajo anti-revmatičnih zdravljenja z zdravili je bila neustrezna. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5. 1), ter za izboljšanje telesne funkcije. psoriasisimraldi je primerna za zdravljenje zmerno do hudo kronično psoriazo v plakih pri odraslih bolniki, ki so kandidati za sistemsko terapijo. pediatrični plaketo psoriasisimraldi je primerna za zdravljenje hudo kronično psoriazo v plakih pri otrocih in mladostnikih od 4 let, ki so imeli ustreznega odgovora ali so neprimerne kandidate za aktualna terapije in phototherapies. hidradenitis suppurativa (hs)imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 in 5. crohnova diseaseimraldi je indiciran za zdravljenje zmerno do hudo aktivno crohnovo boleznijo, pri odraslih bolnikih, ki še niso odzvali, kljub temu polno in ustrezni tečaj zdravljenja s kortikosteroidi in/ali immunosuppressant; ali, ki ne prenašajo ali imajo medicinske kontraindikacije za takšne terapije. paediatric crohn's diseaseimraldi is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or haveulcerative colitisimraldi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisimraldi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisimraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whomcorticosteroid treatment is inappropriate. paediatric uveitisimraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zoetis belgium -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ecuphar veterinaria -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios dr -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

laboratorios dr -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zoetis belgium rue laid burniat 1 1348 louvain -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zoetis belgium sa -